Severe Gastrointestinal Disease: Zepbound (tirzepatide) is associated with gastrointestinal side effects, such as nausea, diarrhea, vomiting, constipation, and stomach pain, and can sometimes be severe
Especially since GLP-1 agonists now have been shown to alter taste and tactile perception in some users
Factors that would result in increased population adoption and utilization are: Growth in off-label use of GLP-1s marketed for diabetes as only Wegovy, Saxenda, and Zepbound (new to market) are approved for weight loss
For example, compounds that preferentially activate G protein pathways may enhance metabolic benefits while reducing side effects
In addition, those who were more sedentary had worse eGFRs and were more likely to die from cardiovascular disease or any cause
Next, determine the initial concentration of the solution (C1)